MeSH term
Frequency | Condition_Probility | *Cleavage Stage, Ovum | 3 | 2.0 |
Embryo Transfer/*standards | 3 | 2.0 |
Female | 357 | 0.0 |
Humans | 1188 | 0.0 |
Meta-Analysis | 3 | 1.0 |
Pregnancy | 6 | 0.0 |
Pregnancy Outcome | 3 | 1.0 |
Pregnancy Rate | 3 | 2.0 |
Pregnancy, Multiple | 3 | 2.0 |
Randomized Controlled Trials | 3 | 0.0 |
Review Literature | 3 | 2.0 |
Albumins/metabolism | 2 | 1.0 |
Albuminuria/*prevention & control | 2 | 2.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 2 | 2.0 |
Hypertension/complications/*drug therapy | 2 | 1.0 |
Indoles/*therapeutic use | 2 | 1.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Animals | 335 | 0.0 |
DNA Damage | 57 | 6.0 |
DNA Repair | 7 | 1.0 |
Drug Resistance, Neoplasm | 14 | 2.0 |
Gene Expression | 65 | 1.0 |
*Education, Medical, Graduate | 6 | 20.0 |
*Educational Status | 6 | 18.0 |
*Students, Medical | 6 | 17.0 |
Surgery/*education | 6 | 16.0 |
Apoptosis/physiology | 11 | 3.0 |
Blotting, Western | 101 | 1.0 |
Enzyme Inhibitors/pharmacology | 24 | 0.0 |
Fluorescent Antibody Technique | 15 | 0.0 |
Immunoprecipitation | 4 | 1.0 |
Mice | 225 | 0.0 |
Mice, Transgenic | 15 | 0.0 |
Nuclear Proteins/*metabolism | 24 | 3.0 |
Protein p53/*metabolism | 169 | 31.0 |
Proto-Oncogene Proteins/*metabolism | 130 | 12.0 |
Research Support, Non-U.S. Gov't | 781 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 312 | 0.0 |
Ubiquitin/*metabolism | 19 | 10.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 8 | 1.0 |
Cells, Cultured | 60 | 0.0 |
Fibroblasts/cytology/physiology | 3 | 3.0 |
Nuclear Proteins/metabolism | 32 | 3.0 |
Phosphoproteins/*metabolism | 3 | 0.0 |
Phosphorylation | 91 | 1.0 |
Proteasome Endopeptidase Complex/metabolism | 2 | 18.0 |
Protein Binding | 115 | 1.0 |
Proto-Oncogene Proteins/metabolism | 88 | 7.0 |
RNA, Small Interfering/genetics/metabolism | 3 | 6.0 |
Rats | 22 | 0.0 |
Serine/metabolism | 15 | 4.0 |
Signal Transduction/*physiology | 7 | 0.0 |
Adult | 201 | 0.0 |
Aged | 188 | 0.0 |
Brain Neoplasms/*genetics | 10 | 6.0 |
Chromosome Deletion | 4 | 0.0 |
Comparative Study | 88 | 0.0 |
DNA Mutational Analysis | 51 | 1.0 |
DNA, Neoplasm/genetics | 17 | 2.0 |
Gene Amplification/genetics | 4 | 6.0 |
Glioblastoma/genetics | 4 | 13.0 |
Immunohistochemistry/methods | 6 | 0.0 |
Loss of Heterozygosity/genetics | 4 | 3.0 |
Male | 282 | 0.0 |
Middle Aged | 213 | 0.0 |
Nucleic Acid Hybridization | 14 | 0.0 |
Sarcoma/genetics | 2 | 20.0 |
Amino Acid Substitution | 15 | 1.0 |
Apoptosis | 68 | 3.0 |
*Nuclear Proteins | 698 | 37.0 |
Protein p53/*physiology | 29 | 23.0 |
Protein-Serine-Threonine Kinases/metabolism | 10 | 1.0 |
Transcription, Genetic | 71 | 1.0 |
Tumor Cells, Cultured | 289 | 1.0 |
Areca/*adverse effects | 5 | 45.0 |
Cell Cycle Proteins/analysis | 4 | 14.0 |
Follow-Up Studies | 17 | 0.0 |
Lymphatic Metastasis | 13 | 1.0 |
Neoplasm Proteins/analysis | 14 | 4.0 |
Neoplasm Staging | 36 | 1.0 |
Prognosis | 96 | 1.0 |
Prospective Studies | 3 | 0.0 |
Tumor Markers, Biological/*analysis | 13 | 1.0 |
Base Sequence | 94 | 0.0 |
Cell Line | 137 | 0.0 |
Feedback, Biochemical | 3 | 7.0 |
Models, Biological | 25 | 0.0 |
Molecular Sequence Data | 132 | 0.0 |
Promoter Regions (Genetics) | 35 | 0.0 |
RNA, Messenger/biosynthesis | 14 | 0.0 |
*Trans-Activation (Genetics) | 17 | 2.0 |
Immunohistochemistry | 199 | 1.0 |
In Situ Hybridization | 17 | 0.0 |
Papillomavirus, Human/metabolism | 2 | 25.0 |
Proto-Oncogene Proteins/biosynthesis | 20 | 11.0 |
Tumor Markers, Biological/*biosynthesis | 2 | 2.0 |
Tumor Virus Infections/metabolism | 2 | 25.0 |
p14ARF Protein/*biosynthesis | 2 | 50.0 |
Adenoviridae/genetics | 17 | 3.0 |
*Apoptosis | 39 | 2.0 |
Cell Cycle | 39 | 3.0 |
Cell Death | 6 | 1.0 |
Cell Separation | 4 | 0.0 |
Fibroblasts/metabolism | 18 | 1.0 |
Flow Cytometry | 30 | 0.0 |
Immunoblotting | 23 | 0.0 |
In Situ Nick-End Labeling | 16 | 2.0 |
Lac Operon | 2 | 1.0 |
Plasmids/metabolism | 36 | 3.0 |
Precipitin Tests | 46 | 1.0 |
Signal Transduction | 28 | 0.0 |
Time Factors | 51 | 0.0 |
Transfection | 157 | 1.0 |
Up-Regulation | 27 | 1.0 |
p14ARF Protein/*metabolism | 7 | 41.0 |
Blotting, Northern | 40 | 0.0 |
Caspases/metabolism | 10 | 1.0 |
Cell Survival | 21 | 1.0 |
Dactinomycin/pharmacology | 9 | 2.0 |
Dose-Response Relationship, Drug | 30 | 0.0 |
Ligands | 8 | 0.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
Microscopy, Fluorescence | 26 | 1.0 |
Protein Synthesis Inhibitors/pharmacology | 5 | 1.0 |
Receptors, Tumor Necrosis Factor/*metabolism | 2 | 0.0 |
*Transcription, Genetic | 17 | 0.0 |
Antineoplastic Agents/pharmacology | 19 | 3.0 |
Cloning, Molecular | 20 | 0.0 |
Doxorubicin/pharmacology | 20 | 9.0 |
Gene Expression Regulation | 40 | 1.0 |
Mutation | 134 | 1.0 |
*Promoter Regions (Genetics) | 10 | 0.0 |
Protein p53/genetics/*metabolism | 85 | 45.0 |
Proto-Oncogene Proteins/genetics/metabolism | 20 | 11.0 |
Aged, 80 and over | 85 | 0.0 |
Gene Expression Regulation, Neoplastic | 61 | 2.0 |
Immunophenotyping | 10 | 0.0 |
Multivariate Analysis | 12 | 0.0 |
Phenotype | 29 | 0.0 |
Predictive Value of Tests | 12 | 0.0 |
Proportional Hazards Models | 10 | 1.0 |
Retrospective Studies | 21 | 0.0 |
Survival Analysis | 35 | 1.0 |
Treatment Outcome | 13 | 0.0 |
Tumor Markers, Biological/genetics/*metabolism | 3 | 8.0 |
Amino Acid Sequence | 91 | 0.0 |
Binding Sites | 39 | 0.0 |
Carrier Proteins/metabolism | 4 | 0.0 |
Exons/genetics | 5 | 0.0 |
Peptide Mapping | 2 | 0.0 |
Protein Structure, Tertiary | 53 | 1.0 |
Protein p53/metabolism | 93 | 15.0 |
Proto-Oncogene Proteins/*antagonists & inhibitors/metabolism | 4 | 20.0 |
Sequence Deletion | 19 | 0.0 |
Bone Neoplasms/pathology | 2 | 12.0 |
Cell Cycle/physiology | 13 | 4.0 |
*Cell Cycle Proteins | 38 | 3.0 |
Cell Division/physiology | 19 | 2.0 |
*DNA-Binding Proteins | 36 | 2.0 |
Fibroblasts/cytology | 10 | 4.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Osteosarcoma/pathology | 2 | 11.0 |
Protein Interaction Mapping | 5 | 4.0 |
Protein p53/deficiency/*physiology | 2 | 40.0 |
Recombinant Fusion Proteins | 8 | 2.0 |
Signal Transduction/physiology | 5 | 0.0 |
Transcription, Genetic/*physiology | 3 | 1.0 |
Cyclins/*metabolism | 23 | 8.0 |
Luciferases/metabolism | 19 | 3.0 |
Plasmids | 3 | 0.0 |
Protein p53/antagonists & inhibitors/genetics/*metabolism | 3 | 100.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 67 | 18.0 |
Retinoblastoma Protein/physiology | 5 | 14.0 |
Trans-Activation (Genetics)/*physiology | 4 | 3.0 |
Transcription Factors/genetics/*metabolism | 13 | 1.0 |
*Chromosome Aberrations | 8 | 1.0 |
*Gene Deletion | 11 | 1.0 |
Loss of Heterozygosity | 13 | 1.0 |
Acetylation | 14 | 2.0 |
Cyclins/genetics | 21 | 14.0 |
Proto-Oncogene Proteins/*physiology | 16 | 7.0 |
Apoptosis/drug effects/physiology | 6 | 6.0 |
Immunoenzyme Techniques | 51 | 1.0 |
Survival Rate | 35 | 1.0 |
Fatal Outcome | 2 | 0.0 |
Histiocytoma, Fibrous/*genetics/metabolism/pathology | 2 | 66.0 |
*Mutation, Missense | 3 | 0.0 |
Proto-Oncogene Proteins/analysis/biosynthesis | 3 | 23.0 |
DNA Methylation | 10 | 1.0 |
DNA, Neoplasm/analysis | 34 | 4.0 |
Gene Deletion | 39 | 2.0 |
Polymerase Chain Reaction | 88 | 0.0 |
Polymorphism, Single-Stranded Conformational | 64 | 3.0 |
Protein p53/*genetics/metabolism | 9 | 23.0 |
Proto-Oncogene Proteins/genetics | 54 | 9.0 |
Apoptosis/drug effects | 12 | 1.0 |
DNA Primers | 34 | 0.0 |
Genes, p53/drug effects/*genetics | 2 | 40.0 |
Necrosis | 2 | 0.0 |
Oncogene Proteins, Viral/genetics | 4 | 11.0 |
Papillomavirus, Human/genetics | 5 | 12.0 |
*Repressor Proteins | 14 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 62 | 0.0 |
Esophageal Neoplasms/*genetics/*pathology | 3 | 33.0 |
*Gene Expression Regulation, Neoplastic | 34 | 2.0 |
Neoplasm Metastasis | 10 | 0.0 |
Protein p53 | 2 | 8.0 |
Proto-Oncogene Proteins/*biosynthesis | 23 | 14.0 |
Antineoplastic Agents/*toxicity | 2 | 3.0 |
Breast Neoplasms | 2 | 0.0 |
Cell Survival/drug effects | 7 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 9 | 0.0 |
Hela Cells | 35 | 0.0 |
Lung Neoplasms | 8 | 7.0 |
Protein p53/*antagonists & inhibitors | 2 | 33.0 |
Proto-Oncogene Proteins/*antagonists & inhibitors | 3 | 12.0 |
Structure-Activity Relationship | 11 | 0.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
Protein Binding/drug effects | 9 | 2.0 |
Chromosome Aberrations | 9 | 1.0 |
Gene Dosage | 6 | 1.0 |
Gene Expression Profiling | 13 | 1.0 |
Genes, Tumor Suppressor | 21 | 2.0 |
Liposarcoma/*genetics/metabolism/pathology | 2 | 66.0 |
Oligonucleotide Array Sequence Analysis | 16 | 1.0 |
Oncogenes | 12 | 4.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Proto-Oncogene Proteins/*genetics/*metabolism | 9 | 19.0 |
RNA, Ribosomal, 5S/metabolism | 2 | 100.0 |
Genes, p53/genetics | 32 | 14.0 |
Models, Molecular | 14 | 0.0 |
Protein Conformation | 23 | 0.0 |
Protein Folding | 2 | 0.0 |
United States | 3 | 0.0 |
Apoptosis/genetics | 13 | 5.0 |
Cell Division/genetics/physiology | 3 | 6.0 |
Gene Expression Regulation, Neoplastic/genetics | 11 | 5.0 |
Gene Therapy/methods | 2 | 2.0 |
Genes, p53 | 69 | 14.0 |
Genetic Vectors/genetics | 4 | 1.0 |
Ovarian Neoplasms/genetics/metabolism/*pathology | 2 | 14.0 |
Proto-Oncogene Proteins/biosynthesis/genetics | 13 | 15.0 |
*Adaptor Proteins, Signal Transducing | 3 | 0.0 |
Caspases/*metabolism | 8 | 3.0 |
Cyclins/metabolism | 38 | 9.0 |
Drug Resistance | 2 | 0.0 |
Enzyme Activation | 17 | 0.0 |
Peptide Hydrolases/metabolism | 4 | 2.0 |
*Protein-Serine-Threonine Kinases | 15 | 1.0 |
Proteins/metabolism | 12 | 1.0 |
COS Cells | 10 | 0.0 |
Catalysis | 8 | 1.0 |
Cercopithecus aethiops | 5 | 0.0 |
Macromolecular Substances | 13 | 0.0 |
Okadaic Acid/pharmacology | 2 | 2.0 |
Protein Processing, Post-Translational/*physiology | 4 | 19.0 |
Recombinant Fusion Proteins/metabolism | 24 | 1.0 |
Species Specificity | 4 | 0.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
*Genes, Tumor Suppressor | 20 | 1.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
*Loss of Heterozygosity | 4 | 1.0 |
Methylation | 3 | 0.0 |
Protein p16/genetics | 7 | 8.0 |
Protein p53/genetics | 25 | 15.0 |
Anoxia | 3 | 3.0 |
Cell Line, Tumor | 52 | 1.0 |
Cell Nucleus/metabolism | 47 | 2.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Disease Progression | 33 | 1.0 |
Flavonoids/pharmacology | 3 | 0.0 |
Genes, Dominant | 5 | 0.0 |
Green Fluorescent Proteins/metabolism | 2 | 3.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Trans-Activation (Genetics) | 62 | 3.0 |
Neoplasms/metabolism | 5 | 5.0 |
Protein Processing, Post-Translational | 12 | 1.0 |
Protein p53/metabolism/*physiology | 3 | 25.0 |
Proto-Oncogene Proteins/metabolism/*physiology | 10 | 20.0 |
Adenoviridae | 3 | 3.0 |
Caspases/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Genetic Vectors | 17 | 1.0 |
Protein p16/*metabolism | 2 | 6.0 |
Retinoblastoma Protein/*metabolism | 13 | 7.0 |
Cell Cycle Proteins/*biosynthesis | 4 | 9.0 |
Cell Nucleus/metabolism/pathology | 4 | 12.0 |
Cyclin D1/biosynthesis | 3 | 7.0 |
Cyclin-Dependent Kinases/biosynthesis | 2 | 6.0 |
G1 Phase/*physiology | 2 | 4.0 |
Protein p16/biosynthesis | 2 | 10.0 |
Protein p53/biosynthesis | 19 | 13.0 |
Retinoblastoma Protein/biosynthesis | 2 | 8.0 |
Breast Neoplasms/*genetics | 7 | 0.0 |
Estrogen Receptor alpha | 4 | 1.0 |
Models, Genetic | 14 | 0.0 |
RNA, Messenger/metabolism | 24 | 0.0 |
Gene Therapy/*methods | 3 | 0.0 |
Oligonucleotides, Antisense/*pharmacology | 10 | 10.0 |
Proto-Oncogene Proteins/*genetics/*pharmacology | 2 | 28.0 |
Microsatellite Repeats/genetics | 3 | 0.0 |
Mutation/*genetics | 12 | 0.0 |
Proto-Oncogene Proteins/*genetics/metabolism | 28 | 19.0 |
RNA, Messenger/genetics/metabolism | 15 | 0.0 |
p14ARF Protein/*genetics/metabolism | 3 | 50.0 |
Cytoplasm/metabolism | 24 | 2.0 |
Down-Regulation | 22 | 1.0 |
Mice, Knockout | 23 | 0.0 |
Proto-Oncogene Proteins/*metabolism/physiology | 3 | 23.0 |
Subcellular Fractions | 6 | 3.0 |
Adolescent | 72 | 0.0 |
Antigens, Nuclear | 5 | 3.0 |
Cell Division | 66 | 1.0 |
Child | 53 | 0.0 |
Child, Preschool | 30 | 0.0 |
Infant | 15 | 0.0 |
Ki-67 Antigen | 2 | 0.0 |
Nuclear Proteins/analysis | 2 | 1.0 |
Proliferating Cell Nuclear Antigen/analysis | 5 | 2.0 |
Protein p53/analysis | 21 | 7.0 |
Proto-Oncogene Proteins/analysis | 21 | 11.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 9 | 4.0 |
Cyclins/biosynthesis/genetics | 7 | 14.0 |
DNA Primers/chemistry | 15 | 1.0 |
Gene Expression Regulation, Neoplastic/*radiation effects | 5 | 23.0 |
Protein Biosynthesis | 13 | 0.0 |
Protein p53/biosynthesis/genetics | 4 | 8.0 |
Proteins/*genetics | 11 | 0.0 |
*Proto-Oncogene Proteins c-bcl-2 | 14 | 3.0 |
Ultraviolet Rays | 28 | 4.0 |
Cell Cycle/radiation effects | 3 | 10.0 |
Dose-Response Relationship, Radiation | 8 | 2.0 |
Proto-Oncogene Proteins/genetics/*physiology | 14 | 16.0 |
Transcription Factors/metabolism | 20 | 1.0 |
p14ARF Protein/physiology | 2 | 66.0 |
Carcinoma/*genetics/metabolism/pathology | 2 | 16.0 |
*DNA Methylation | 4 | 0.0 |
Neoplasm Proteins/genetics/metabolism | 11 | 10.0 |
Protein p16/*genetics/metabolism | 3 | 15.0 |
Microscopy, Electron | 7 | 0.0 |
Cyclins/biosynthesis | 18 | 18.0 |
*Alternative Splicing | 8 | 1.0 |
Neoplasm Proteins/genetics | 28 | 5.0 |
Proto-Oncogene Proteins/*genetics | 87 | 9.0 |
RNA, Neoplasm/genetics | 6 | 1.0 |
Rhabdomyosarcoma/*genetics/pathology | 2 | 18.0 |
Carcinoma, Squamous Cell/*metabolism | 5 | 4.0 |
Cyclin D1/metabolism | 6 | 4.0 |
Risk Factors | 7 | 0.0 |
Apoptosis/*physiology | 17 | 2.0 |
Cell Survival/physiology | 3 | 1.0 |
JNK Mitogen-Activated Protein Kinases | 5 | 0.0 |
*MAP Kinase Kinase Kinase 1 | 2 | 1.0 |
Cysteine Endopeptidases | 4 | 8.0 |
Ligases/metabolism | 4 | 6.0 |
Multienzyme Complexes/*antagonists & inhibitors | 4 | 22.0 |
Proteasome Endopeptidase Complex | 39 | 7.0 |
Ubiquitin/metabolism | 30 | 13.0 |
Ubiquitin-Protein Ligases | 14 | 6.0 |
Analysis of Variance | 6 | 0.0 |
Neoplasm Proteins/*analysis | 22 | 6.0 |
Protein p53/*analysis | 36 | 19.0 |
Proto-Oncogene Proteins/*analysis | 35 | 21.0 |
Proto-Oncogene Proteins c-bcl-2/*analysis | 5 | 5.0 |
Clinical Trials | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/physiology | 5 | 3.0 |
Genes, p53/*genetics | 49 | 14.0 |
Proto-Oncogene Proteins/physiology | 7 | 5.0 |
Alleles | 13 | 0.0 |
Amino Acid Motifs | 4 | 0.0 |
Leucine/chemistry | 2 | 5.0 |
Peptide Library | 6 | 4.0 |
Protein Structure, Secondary | 2 | 0.0 |
Protein p53/*chemistry | 3 | 37.0 |
Proto-Oncogene Proteins/*chemistry/metabolism | 6 | 30.0 |
Sequence Homology, Amino Acid | 28 | 0.0 |
Serine/chemistry | 6 | 4.0 |
Lung Neoplasms/metabolism/pathology | 2 | 11.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 3 | 1.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Chromones/pharmacology | 2 | 0.0 |
Morpholines/pharmacology | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism/*physiology | 3 | 37.0 |
Recombinant Proteins/metabolism | 28 | 1.0 |
Subcellular Fractions/metabolism | 5 | 1.0 |
Chromosomes, Human, Pair 12/*genetics | 7 | 5.0 |
Extremities | 3 | 11.0 |
Neoplasm Recurrence, Local/genetics | 2 | 9.0 |
Gene Amplification/*genetics | 11 | 10.0 |
*Oligonucleotide Array Sequence Analysis | 4 | 2.0 |
*Pulmonary Artery | 2 | 66.0 |
Sarcoma/*genetics | 11 | 32.0 |
Gene Amplification | 70 | 9.0 |
Protein p53/analysis/*genetics | 3 | 23.0 |
Proto-Oncogene Proteins/analysis/*genetics | 10 | 21.0 |
Mutation, Missense | 5 | 0.0 |
Protein p53/analysis/genetics | 9 | 39.0 |
Proto-Oncogene Proteins c-myc/analysis | 2 | 11.0 |
Testicular Neoplasms/genetics/*metabolism/pathology | 2 | 33.0 |
Drug Synergism | 10 | 0.0 |
Mice, Nude | 33 | 1.0 |
Neoplasm Transplantation | 19 | 1.0 |
Oligonucleotides, Antisense/*therapeutic use | 4 | 28.0 |
Xenograft Model Antitumor Assays | 5 | 2.0 |
*Gene Therapy | 6 | 1.0 |
*Genes, p53 | 76 | 15.0 |
Electrophoretic Mobility Shift Assay | 4 | 0.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
Cell Cycle Proteins/*genetics | 3 | 1.0 |
Genes, p53/*physiology | 8 | 17.0 |
*Mutation | 41 | 0.0 |
Nuclear Proteins/*genetics | 12 | 2.0 |
RNA, Messenger/analysis | 16 | 0.0 |
p14ARF Protein/*genetics | 7 | 28.0 |
Camptothecin/pharmacology | 2 | 4.0 |
Nuclear Proteins/*genetics/metabolism | 9 | 6.0 |
Protein Transport | 11 | 1.0 |
Cell Cycle/*physiology | 9 | 3.0 |
DNA Replication | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 10 | 0.0 |
G0 Phase | 2 | 2.0 |
Microinjections | 2 | 0.0 |
*DNA Damage | 22 | 3.0 |
Kinetics | 16 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 6 | 1.0 |
p38 Mitogen-Activated Protein Kinases | 3 | 0.0 |
Cell Cycle/drug effects | 14 | 2.0 |
Protein p53/chemistry/genetics/*metabolism | 11 | 55.0 |
RNA, Neoplasm/biosynthesis | 3 | 2.0 |
Radiation-Protective Agents/*pharmacology | 2 | 10.0 |
Temperature | 14 | 1.0 |
Cycloheximide/pharmacology | 7 | 1.0 |
Gene Expression Regulation/drug effects | 6 | 0.0 |
Osteosarcoma | 8 | 8.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 50 | 0.0 |
Zinc Fingers | 12 | 2.0 |
Alternative Splicing | 12 | 1.0 |
Protein Isoforms | 5 | 0.0 |
DNA, Neoplasm/biosynthesis | 2 | 1.0 |
DNA-Binding Proteins/metabolism | 16 | 0.0 |
Protein p53/biosynthesis/genetics/*physiology | 4 | 50.0 |
S Phase/physiology | 3 | 3.0 |
Breast Neoplasms/*genetics/pathology | 5 | 2.0 |
Carcinoma, Ductal, Breast/*genetics/pathology | 2 | 7.0 |
Cell Nucleus/chemistry | 6 | 3.0 |
Codon/genetics | 2 | 0.0 |
Cytoplasm/chemistry | 4 | 2.0 |
Point Mutation | 23 | 1.0 |
Proto-Oncogene Proteins/*biosynthesis/genetics | 16 | 18.0 |
RNA, Messenger/*genetics | 3 | 0.0 |
DNA, Complementary | 10 | 0.0 |
DNA, Neoplasm/*analysis | 4 | 2.0 |
Data Interpretation, Statistical | 3 | 1.0 |
English Abstract | 43 | 0.0 |
Nasopharyngeal Neoplasms/*genetics | 3 | 14.0 |
Protein p53/*genetics | 22 | 13.0 |
Antibiotics, Antineoplastic/*pharmacology | 4 | 3.0 |
Apoptosis/*drug effects | 20 | 2.0 |
Cell Cycle Proteins/biosynthesis | 3 | 11.0 |
Doxorubicin/*pharmacology | 5 | 7.0 |
Tetrazolium Salts | 2 | 3.0 |
Thiazoles | 2 | 3.0 |
Ameloblastoma/*metabolism/pathology | 2 | 40.0 |
Jaw Neoplasms/*metabolism/pathology | 2 | 66.0 |
Case-Control Studies | 4 | 0.0 |
DNA, Complementary/analysis | 3 | 1.0 |
*Gene Expression Regulation, Leukemic | 4 | 4.0 |
Neoplasm Proteins/genetics/*metabolism | 12 | 6.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Autoantibodies/immunology | 2 | 1.0 |
Fluorescent Antibody Technique, Indirect | 3 | 0.0 |
*Membrane Proteins | 12 | 1.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Adenoviridae/*genetics | 7 | 2.0 |
Cell Adhesion | 2 | 0.0 |
Gene Therapy | 3 | 0.0 |
Proteins/genetics/*metabolism | 6 | 1.0 |
3T3 Cells/metabolism | 2 | 7.0 |
Consensus Sequence | 4 | 0.0 |
Cysteine Endopeptidases/metabolism | 21 | 9.0 |
Cysteine Proteinase Inhibitors/pharmacology | 10 | 4.0 |
Doxycycline/pharmacology | 3 | 5.0 |
Ethylmaleimide/pharmacology | 3 | 5.0 |
Feedback | 8 | 4.0 |
Half-Life | 11 | 1.0 |
Multienzyme Complexes/metabolism | 20 | 10.0 |
Mutagenesis, Site-Directed | 19 | 0.0 |
Peptide Fragments/metabolism | 4 | 1.0 |
*Protein Processing, Post-Translational | 3 | 1.0 |
Proto-Oncogene Proteins/chemistry/genetics/*metabolism | 9 | 16.0 |
Recombinant Fusion Proteins/physiology | 3 | 1.0 |
Apoptosis/genetics/*physiology | 5 | 13.0 |
Carrier Proteins/*physiology | 2 | 0.0 |
DNA, Complementary/genetics | 8 | 0.0 |
*Gene Expression Regulation | 17 | 0.0 |
Lung Neoplasms/pathology | 3 | 5.0 |
*Transcription Factors | 2 | 0.0 |
Cell Transformation, Neoplastic | 11 | 1.0 |
In Situ Hybridization, Fluorescence | 27 | 0.0 |
Karyotyping | 15 | 0.0 |
Translocation, Genetic | 5 | 0.0 |
Bladder Neoplasms/*metabolism/pathology | 5 | 15.0 |
Carcinoma, Transitional Cell/*metabolism/pathology | 3 | 17.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 6 | 2.0 |
Cell Differentiation | 16 | 0.0 |
Cyclin-Dependent Kinases/*metabolism | 2 | 0.0 |
Ploidies | 4 | 1.0 |
Thyroid Neoplasms/*chemistry/pathology | 2 | 33.0 |
Cell Survival/drug effects/radiation effects | 2 | 4.0 |
Clone Cells | 4 | 0.0 |
Radiation, Ionizing | 7 | 4.0 |
Transcription, Genetic/drug effects | 5 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Two-Hybrid System Techniques | 12 | 1.0 |
Disease-Free Survival | 14 | 1.0 |
Regression Analysis | 3 | 0.0 |
Risk Assessment | 4 | 0.0 |
Caspases/antagonists & inhibitors | 3 | 6.0 |
DNA-Binding Proteins/genetics | 5 | 0.0 |
Nuclear Proteins/analysis/genetics | 2 | 22.0 |
Phosphoproteins/genetics | 2 | 1.0 |
Rabbits | 6 | 0.0 |
Age Factors | 9 | 0.0 |
Brain Neoplasms/*genetics/metabolism/pathology | 2 | 8.0 |
Immunocompetence | 2 | 4.0 |
Lymphoma, B-Cell/*genetics/metabolism/pathology | 2 | 28.0 |
Protein p16/*genetics | 5 | 5.0 |
Ki-67 Antigen/metabolism | 12 | 5.0 |
Receptor, Epidermal Growth Factor/metabolism | 3 | 0.0 |
Survivors | 2 | 2.0 |
Bladder Neoplasms/*genetics/metabolism/pathology | 2 | 14.0 |
Cyclins/genetics/metabolism | 4 | 7.0 |
DNA, Neoplasm/metabolism | 4 | 2.0 |
Enzyme Inhibitors/metabolism | 14 | 6.0 |
Genotype | 11 | 0.0 |
Mutation/genetics | 15 | 1.0 |
Cytosol/metabolism | 2 | 0.0 |
Etoposide/pharmacology | 12 | 8.0 |
Liver/metabolism | 2 | 0.0 |
Spleen/metabolism | 2 | 1.0 |
Staurosporine/pharmacology | 2 | 1.0 |
Threonine/metabolism | 4 | 4.0 |
Plasmids/genetics | 7 | 1.0 |
Bone Neoplasms/*genetics/pathology | 6 | 50.0 |
Chromosome Banding | 3 | 0.0 |
Osteosarcoma/*genetics/pathology | 3 | 33.0 |
*Chromosome Deletion | 2 | 0.0 |
DNA Damage/genetics | 3 | 7.0 |
Fibroblasts | 10 | 1.0 |
Heterozygote | 7 | 0.0 |
Mice, SCID | 4 | 0.0 |
Mutagenesis/genetics | 3 | 7.0 |
Protein p53/*antagonists & inhibitors/*metabolism | 2 | 100.0 |
Proto-Oncogene Proteins/*antagonists & inhibitors/*metabolism | 3 | 60.0 |
*Cell Transformation, Neoplastic | 5 | 1.0 |
Cyclin D1/analysis | 4 | 10.0 |
Epithelial Cells/pathology | 2 | 2.0 |
Protein p53/physiology | 9 | 11.0 |
Cell Cycle Proteins/*analysis | 2 | 11.0 |
Enzyme Inhibitors/*analysis | 3 | 25.0 |
Tumor Suppressor Proteins/*analysis | 2 | 14.0 |
*Cell Aging/genetics | 2 | 100.0 |
*Cell Division | 3 | 1.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors | 3 | 2.0 |
Cyclins/genetics/physiology | 2 | 22.0 |
Tumor Markers, Biological/metabolism | 6 | 1.0 |
Antineoplastic Agents/*pharmacology | 18 | 1.0 |
Cisplatin/*pharmacology | 7 | 5.0 |
Protein p53/analysis/*physiology | 5 | 55.0 |
*Proteins | 5 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/genetics | 3 | 2.0 |
Allosteric Site | 2 | 7.0 |
DNA/metabolism | 23 | 1.0 |
Protein p53/*chemistry/*metabolism | 3 | 75.0 |
DNA, Neoplasm/isolation & purification | 5 | 17.0 |
*Genes, p16 | 5 | 5.0 |
*Genes, p53/genetics | 2 | 50.0 |
*Tumor Markers, Biological | 6 | 3.0 |
RNA, Neoplasm/analysis | 4 | 1.0 |
*Down-Regulation | 2 | 0.0 |
Glutathione Transferase/metabolism | 16 | 2.0 |
Cell Division/drug effects | 15 | 0.0 |
Cisplatin/pharmacology | 6 | 3.0 |
Inhibitory Concentration 50 | 4 | 1.0 |
Rhabdomyosarcoma/genetics/metabolism/*pathology | 2 | 40.0 |
Tumor Cells, Cultured/drug effects | 4 | 0.0 |
Disease Models, Animal | 7 | 0.0 |
Genes, p16 | 5 | 5.0 |
Oncogene Proteins, Viral/genetics/metabolism | 4 | 33.0 |
Proto-Oncogene Proteins | 2 | 5.0 |
Tumor Suppressor Proteins/*metabolism | 3 | 3.0 |
p14ARF Protein/genetics/*metabolism | 6 | 66.0 |
3T3 Cells | 24 | 1.0 |
Active Transport, Cell Nucleus/physiology | 3 | 5.0 |
Cell Nucleolus/chemistry/metabolism | 2 | 50.0 |
Genes, Reporter | 34 | 1.0 |
Neoplasm Proteins/metabolism | 27 | 6.0 |
Nuclear Proteins/genetics/metabolism | 10 | 5.0 |
Tumor Suppressor Proteins/genetics/*metabolism | 3 | 5.0 |
DNA-Binding Proteins/genetics/metabolism | 4 | 0.0 |
Cyclins/analysis | 7 | 16.0 |
Protein p53/*biosynthesis/genetics | 8 | 21.0 |
Acute Disease | 2 | 0.0 |
Inflammation | 2 | 0.0 |
Recurrence | 6 | 0.0 |
Adenovirus E4 Proteins/*metabolism | 2 | 40.0 |
CHO Cells | 2 | 0.0 |
Cell Cycle Proteins/*metabolism | 7 | 2.0 |
Hamsters | 5 | 0.0 |
Microscopy, Confocal | 8 | 0.0 |
Molecular Weight | 8 | 0.0 |
Dyes/pharmacology | 2 | 2.0 |
Neoplasms/*drug therapy | 2 | 1.0 |
Retroviridae/genetics | 8 | 2.0 |
Transduction, Genetic | 4 | 1.0 |
Arrestins/*physiology | 2 | 33.0 |
Neoplasm Proteins/biosynthesis/genetics/*metabolism | 2 | 50.0 |
Neoplasms/genetics/*metabolism | 5 | 20.0 |
*Protein Biosynthesis | 4 | 0.0 |
Lung Neoplasms/*genetics/pathology | 6 | 6.0 |
Proto-Oncogene Proteins/biosynthesis/*genetics | 13 | 20.0 |
Adenocarcinoma/genetics/metabolism/pathology | 3 | 10.0 |
Cell Line, Transformed | 13 | 0.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 6 | 5.0 |
Proto-Oncogene Proteins/antagonists & inhibitors/*metabolism | 5 | 19.0 |
Receptor, erbB-2/genetics/*metabolism | 2 | 6.0 |
Trans-Activators/metabolism | 9 | 0.0 |
Ubiquitins/*metabolism | 15 | 9.0 |
p14ARF Protein/metabolism | 8 | 50.0 |
Protein p53/*biosynthesis | 18 | 14.0 |
Apoptosis/*genetics | 13 | 5.0 |
Neoplasm Proteins/*metabolism | 35 | 6.0 |
Oncogenes/*genetics | 8 | 10.0 |
*Active Transport, Cell Nucleus | 4 | 10.0 |
Cell Nucleus/*metabolism | 17 | 3.0 |
Lysine/chemistry | 6 | 7.0 |
*Receptors, Cytoplasmic and Nuclear | 2 | 2.0 |
Cell Cycle Proteins/*physiology | 4 | 7.0 |
Chromatin/metabolism | 3 | 1.0 |
Protein p53/chemistry/*metabolism | 13 | 72.0 |
Camptothecin/*analogs & derivatives/therapeutic use | 2 | 28.0 |
Cyclins/drug effects/metabolism | 2 | 11.0 |
Doxorubicin/therapeutic use | 4 | 7.0 |
Drug Therapy, Combination | 2 | 0.0 |
Fluorouracil/therapeutic use | 2 | 4.0 |
Cyclin-Dependent Kinases/genetics/metabolism | 3 | 10.0 |
Infant, Newborn | 2 | 0.0 |
Protein p53/genetics/physiology | 4 | 17.0 |
Protein-Serine-Threonine Kinases/genetics/metabolism | 3 | 2.0 |
Proto-Oncogene Proteins/genetics/physiology | 4 | 12.0 |
Point Mutation/genetics | 3 | 1.0 |
Protein p53/*chemistry/genetics/*metabolism | 5 | 45.0 |
Sequence Alignment | 14 | 0.0 |
Sequence Deletion/genetics | 3 | 1.0 |
Carcinoma, Squamous Cell/*metabolism/pathology | 3 | 3.0 |
Ki-67 Antigen/analysis | 14 | 5.0 |
Statistics, Nonparametric | 6 | 0.0 |
*CDC2-CDC28 Kinases | 3 | 0.0 |
Cell Aging/*physiology | 2 | 3.0 |
Cyclin-Dependent Kinases/genetics | 12 | 20.0 |
Gene Expression/physiology | 3 | 0.0 |
Protein-Serine-Threonine Kinases/genetics | 2 | 1.0 |
Transcription Factors/*genetics | 9 | 0.0 |
Active Transport, Cell Nucleus | 13 | 5.0 |
Dimerization | 3 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
Oligonucleotides, Antisense/pharmacology | 4 | 1.0 |
Proto-Oncogene Proteins/biosynthesis/genetics/*physiology | 2 | 8.0 |
Pyrimidines/pharmacology | 2 | 1.0 |
Neoplasm Proteins/antagonists & inhibitors/metabolism | 3 | 50.0 |
Protein p53/*antagonists & inhibitors/chemistry/genetics/*metabolism | 2 | 100.0 |
Xenopus laevis | 2 | 0.0 |
Gene Library | 4 | 0.0 |
Protein p53/*antagonists & inhibitors/genetics | 2 | 100.0 |
Fibroblasts/metabolism/radiation effects | 2 | 10.0 |
Genes, p53/radiation effects | 2 | 33.0 |
Protein p53/metabolism/*radiation effects | 2 | 66.0 |
Neoplasm Proteins/immunology | 2 | 5.0 |
Protein p53/immunology | 2 | 33.0 |
Binding Sites/genetics | 3 | 0.0 |
In Vitro | 16 | 0.0 |
Mutagenesis | 10 | 0.0 |
Signal Transduction/genetics | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Viral Proteins/genetics/metabolism | 2 | 5.0 |
Epitopes | 3 | 0.0 |
Hydrolysis | 6 | 0.0 |
Protein p16/biosynthesis/genetics | 2 | 20.0 |
Proteins/genetics | 7 | 0.0 |
Sequence Analysis, DNA | 17 | 0.0 |
p14ARF Protein | 38 | 48.0 |
*Chromosomes, Human, Pair 12 | 16 | 5.0 |
Osteosarcoma/genetics/*metabolism/pathology | 2 | 100.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 8 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 14 | 4.0 |
Brain Neoplasms/*genetics/pathology | 5 | 7.0 |
DNA, Neoplasm/chemistry/genetics | 4 | 3.0 |
DNA-Binding Proteins/*genetics/metabolism | 6 | 1.0 |
Glioma/*genetics/pathology | 2 | 6.0 |
*Immediate-Early Proteins | 2 | 0.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
Transcription Factors/*genetics/metabolism | 2 | 0.0 |
Cyclins/analysis/biosynthesis | 3 | 75.0 |
Cell Transformation, Neoplastic/genetics | 5 | 1.0 |
Genes, Retinoblastoma | 7 | 7.0 |
Cell Cycle Proteins/metabolism | 9 | 2.0 |
Cyclin E/metabolism | 3 | 2.0 |
Esophageal Neoplasms/epidemiology/*genetics | 2 | 25.0 |
Incidence | 3 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Neoplasm Proteins/*genetics/metabolism | 10 | 6.0 |
Phosphoproteins/*genetics/metabolism | 2 | 5.0 |
Protein p16/metabolism | 3 | 5.0 |
Trans-Activators/*genetics/metabolism | 3 | 2.0 |
*Tumor Suppressor Proteins | 9 | 0.0 |
*Genes, Lethal | 2 | 7.0 |
Adenocarcinoma/*metabolism/pathology | 3 | 2.0 |
Colorectal Neoplasms/*metabolism/pathology | 2 | 4.0 |
Mitotic Index | 2 | 1.0 |
Tumor Markers, Biological/*metabolism | 11 | 2.0 |
Genetic Markers | 11 | 0.0 |
Protein p53/chemistry/genetics/*physiology | 2 | 50.0 |
Cyclin-Dependent Kinases/*genetics | 8 | 12.0 |
Diagnosis, Differential | 7 | 0.0 |
Liposarcoma/*genetics/pathology | 5 | 100.0 |
Mouth Neoplasms/*genetics/pathology | 2 | 11.0 |
Neoplasm Proteins/*genetics | 32 | 3.0 |
Kidney | 2 | 0.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
*Translocation, Genetic | 3 | 0.0 |
*Radiation Tolerance | 2 | 3.0 |
*G1 Phase | 4 | 8.0 |
Imidazoles/pharmacology | 2 | 0.0 |
Nuclear Proteins | 2 | 4.0 |
Pyridines/pharmacology | 2 | 0.0 |
Trans-Activators/*physiology | 4 | 1.0 |
Protein p53/antagonists & inhibitors/*physiology | 3 | 60.0 |
Blotting, Southern | 44 | 1.0 |
Bone Neoplasms/*genetics/metabolism | 2 | 33.0 |
Tumor Markers, Biological/analysis | 9 | 1.0 |
Ubiquitin-Conjugating Enzymes | 4 | 8.0 |
*Immunophenotyping | 2 | 1.0 |
Protein p53/*analysis/immunology | 2 | 33.0 |
Proto-Oncogene Proteins/*analysis/immunology | 3 | 27.0 |
DNA Damage/drug effects | 2 | 4.0 |
Phosphorylation/drug effects | 4 | 0.0 |
Cisplatin/administration & dosage | 2 | 0.0 |
Combined Modality Therapy | 8 | 0.0 |
Mice, Inbred BALB C | 13 | 0.0 |
Protein p53/biosynthesis/*genetics | 7 | 46.0 |
Chromosome Disorders | 4 | 1.0 |
Neoplasm Invasiveness | 12 | 1.0 |
Antibiotics, Antineoplastic/pharmacology | 4 | 4.0 |
Cell Fractionation | 4 | 1.0 |
Cytoplasm/*metabolism | 4 | 3.0 |
Fatty Acids, Unsaturated/pharmacology | 6 | 9.0 |
Oxygen/metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 7 | 0.0 |
Transcription Factors/*metabolism | 10 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Cytochrome c Group/metabolism | 3 | 2.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
Promoter Regions (Genetics)/genetics | 7 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 15 | 3.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
*Trans-Activators | 9 | 1.0 |
Genes, Tumor Suppressor/*genetics | 7 | 2.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine/pharmacology | 2 | 6.0 |
Cell Nucleus/pathology | 2 | 2.0 |
Lung Neoplasms/*genetics | 4 | 1.0 |
Neuroblastoma/*genetics | 6 | 6.0 |
Cell Compartmentation | 2 | 0.0 |
Serine/genetics | 2 | 2.0 |
*Zinc Fingers | 4 | 1.0 |
Proteins/physiology | 3 | 2.0 |
Lung Neoplasms/genetics/*metabolism/pathology | 2 | 7.0 |
Protein p53/genetics/immunology/*metabolism | 4 | 100.0 |
Microsatellite Repeats | 9 | 0.0 |
Molecular Biology/methods | 2 | 7.0 |
Protein p16/genetics/metabolism | 4 | 15.0 |
*Chromosome Mapping | 2 | 0.0 |
Chromosomes, Human, Pair 9/*genetics | 2 | 1.0 |
Cyclin D1/genetics | 4 | 6.0 |
Sarcoma, Ewing's/*genetics | 3 | 6.0 |
Transplantation, Heterologous | 5 | 0.0 |
Gamma Rays | 13 | 5.0 |
Protein Synthesis Inhibitors/metabolism | 2 | 16.0 |
Ribosomal Proteins/genetics/*metabolism | 2 | 22.0 |
Cell Division/genetics | 12 | 3.0 |
Neoplasm Proteins/*biosynthesis/genetics | 6 | 3.0 |
Nuclear Proteins/*antagonists & inhibitors/metabolism | 2 | 40.0 |
Chemotherapy, Adjuvant | 3 | 1.0 |
Neoplasm Recurrence, Local | 9 | 2.0 |
Apoptosis/radiation effects | 2 | 5.0 |
Cyclins/*biosynthesis | 4 | 7.0 |
*Genes, myc | 5 | 2.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 6 | 6.0 |
Gene Transfer Techniques | 5 | 0.0 |
Luciferases/genetics | 7 | 2.0 |
Methyl Methanesulfonate/pharmacology | 4 | 10.0 |
Saccharomyces cerevisiae | 3 | 1.0 |
Ligases/*metabolism | 6 | 6.0 |
Proto-Oncogene Proteins/chemistry/*metabolism | 7 | 12.0 |
Liver Neoplasms/*genetics/pathology | 2 | 8.0 |
*Nucleic Acid Hybridization | 2 | 3.0 |
Sarcoma/*genetics/pathology | 2 | 28.0 |
Retinoblastoma Protein/metabolism | 11 | 3.0 |
Genes, p16/genetics | 3 | 13.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
RNA Probes | 2 | 1.0 |
*Gene Amplification | 49 | 12.0 |
Glioblastoma/*genetics | 10 | 14.0 |
*Oncogenes | 12 | 2.0 |
Ovarian Neoplasms/*metabolism/pathology | 2 | 3.0 |
Protein p53/biosynthesis/*metabolism | 2 | 28.0 |
Protein p53/*analysis/genetics | 3 | 14.0 |
Proto-Oncogene Proteins/*analysis/genetics | 4 | 12.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 4 | 0.0 |
Proliferating Cell Nuclear Antigen/metabolism | 4 | 1.0 |
Binding, Competitive | 2 | 0.0 |
Adenovirus E1A Proteins/genetics/metabolism | 2 | 22.0 |
Trans-Activators/*metabolism | 9 | 0.0 |
Cyclins/*analysis | 12 | 30.0 |
Ki-67 Antigen/*analysis | 8 | 11.0 |
Protein p16/*analysis | 3 | 25.0 |
Statistics | 2 | 0.0 |
Cell Nucleolus/*metabolism | 7 | 22.0 |
Proteins/*metabolism | 13 | 1.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
DNA Damage/*physiology/radiation effects | 2 | 22.0 |
Epitope Mapping | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*metabolism | 13 | 1.0 |
Proto-Oncogene Proteins/genetics/immunology/*metabolism | 2 | 28.0 |
*Carrier Proteins | 19 | 3.0 |
Conserved Sequence | 6 | 0.0 |
Protein Structure, Tertiary/physiology | 3 | 1.0 |
Trans-Activators/genetics/*metabolism | 4 | 1.0 |
Biotransformation | 2 | 0.0 |
Protein p53/genetics/*physiology | 6 | 17.0 |
Bone Neoplasms/*genetics/metabolism/pathology | 5 | 50.0 |
*Genes, ras | 5 | 2.0 |
Osteosarcoma/*genetics/metabolism/pathology | 4 | 57.0 |
G1 Phase | 14 | 4.0 |
Nuclear Proteins/*physiology | 7 | 5.0 |
RNA, Small Interfering/metabolism | 4 | 2.0 |
Chloramphenicol O-Acetyltransferase/metabolism | 3 | 2.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Exons/physiology | 2 | 11.0 |
Mutagenesis/physiology | 4 | 5.0 |
Osteosarcoma/genetics/metabolism | 2 | 20.0 |
Protein p53/analysis/*metabolism | 3 | 50.0 |
Transcription, Genetic/*drug effects | 5 | 1.0 |
Cell Cycle/*drug effects | 4 | 2.0 |
S Phase | 8 | 2.0 |
Promoter Regions (Genetics)/*genetics | 5 | 0.0 |
HT29 Cells | 2 | 1.0 |
Chromosomes, Human, Pair 9/genetics | 5 | 4.0 |
Homozygote | 6 | 0.0 |
Proteins/*genetics/metabolism | 2 | 0.0 |
Cysteine Endopeptidases/*metabolism | 8 | 3.0 |
Down-Regulation/physiology | 3 | 3.0 |
HL-60 Cells | 4 | 0.0 |
Multienzyme Complexes/*metabolism | 8 | 5.0 |
Poly(ADP-ribose) Polymerases/*metabolism | 3 | 14.0 |
5' Untranslated Regions/genetics | 2 | 1.0 |
Breast/metabolism | 2 | 2.0 |
RNA, Messenger/*genetics/metabolism | 3 | 4.0 |
*Gene Silencing | 2 | 1.0 |
Proteins/*genetics/physiology | 2 | 2.0 |
Gene Expression Regulation, Neoplastic/radiation effects | 3 | 23.0 |
Glioblastoma/*genetics/metabolism | 2 | 16.0 |
Neoplasm Proteins/biosynthesis/genetics | 6 | 4.0 |
*Sequence Deletion | 3 | 0.0 |
Trans-Activation (Genetics)/radiation effects | 2 | 50.0 |
*Ultraviolet Rays | 7 | 3.0 |
Ki-67 Antigen/biosynthesis | 6 | 7.0 |
Neoplasm Proteins/biosynthesis | 7 | 9.0 |
Proliferating Cell Nuclear Antigen/biosynthesis | 2 | 4.0 |
Cell Nucleolus/metabolism | 5 | 13.0 |
*Point Mutation | 10 | 0.0 |
Peptide Fragments/physiology | 2 | 6.0 |
Tumor Cells, Cultured/metabolism | 3 | 1.0 |
Cell Membrane/metabolism | 3 | 0.0 |
K562 Cells | 4 | 0.0 |
ras Proteins/*metabolism | 2 | 1.0 |
Peptide Hydrolases/*metabolism | 2 | 2.0 |
*Proteasome Endopeptidase Complex | 5 | 7.0 |
Proto-Oncogene Protein p21(ras)/metabolism | 4 | 5.0 |
*Signal Transduction | 7 | 0.0 |
Casein Kinase II | 4 | 3.0 |
Cell Division/*physiology | 3 | 1.0 |
Ovarian Neoplasms/pathology | 2 | 6.0 |
RNA, Messenger/genetics | 12 | 0.0 |
Suppression, Genetic | 2 | 3.0 |
*TATA-Binding Protein Associated Factors | 4 | 4.0 |
*Transcription Factor TFIID | 3 | 5.0 |
Ubiquitins/metabolism | 13 | 9.0 |
Enzyme Inhibitors/analysis | 7 | 63.0 |
Lung Neoplasms/*pathology | 3 | 4.0 |
Retinoblastoma Protein/*analysis | 3 | 21.0 |
Adenocarcinoma/genetics/*pathology | 2 | 9.0 |
Proto-Oncogene Proteins/pharmacology | 2 | 9.0 |
DNA-Binding Proteins/*genetics | 4 | 0.0 |
WT1 Proteins | 2 | 0.0 |
Binding Sites/drug effects | 2 | 3.0 |
Phosphoserine/metabolism | 5 | 6.0 |
Proto-Oncogene Proteins/antagonists & inhibitors/metabolism | 2 | 9.0 |
TATA-Box Binding Protein | 2 | 0.0 |
Yeasts/genetics | 2 | 2.0 |
Recombinant Proteins/genetics/metabolism | 7 | 1.0 |
Luciferases/biosynthesis/genetics | 2 | 3.0 |
Proto-Oncogene Proteins/biosynthesis/*metabolism | 2 | 9.0 |
Neoplasm Proteins/*biosynthesis | 9 | 9.0 |
Cyclin D1/*metabolism | 2 | 3.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors | 3 | 3.0 |
*Muscle Proteins | 3 | 1.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Colonic Neoplasms/*genetics | 2 | 2.0 |
Exons | 14 | 0.0 |
Protein p16 | 8 | 5.0 |
DNA-Binding Proteins/antagonists & inhibitors/genetics/*metabolism | 2 | 9.0 |
Nuclear Proteins/antagonists & inhibitors/genetics/*metabolism | 2 | 66.0 |
Substrate Specificity | 7 | 0.0 |
Mitomycin/pharmacology | 2 | 2.0 |
Actins/analysis | 2 | 1.0 |
*Gene Expression | 6 | 0.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Sarcoma/chemistry/*genetics/pathology | 2 | 66.0 |
Vimentin/analysis | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 10 | 2.0 |
Jurkat Cells | 5 | 0.0 |
Nuclear Proteins/chemistry/genetics/*metabolism | 4 | 4.0 |
Phosphoproteins/chemistry/genetics/*metabolism | 2 | 4.0 |
Protein p53/chemistry/metabolism | 2 | 40.0 |
Depression, Chemical | 2 | 1.0 |
G2 Phase/drug effects | 2 | 4.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 4 | 1.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Neoplasms/*drug therapy/*enzymology | 2 | 20.0 |
Cell Division/*genetics | 3 | 5.0 |
Proto-Oncogene Protein p21(ras)/biosynthesis | 5 | 38.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 5 | 3.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Estradiol/pharmacology | 3 | 1.0 |
Receptors, Estrogen/*metabolism | 2 | 0.0 |
Green Fluorescent Proteins | 5 | 0.0 |
Luminescent Proteins/metabolism | 6 | 1.0 |
Nuclear Localization Signal | 4 | 5.0 |
*Cell Differentiation | 2 | 0.0 |
Keratinocytes/cytology/*metabolism | 2 | 5.0 |
*Gene Expression Profiling | 6 | 1.0 |
Oligodeoxyribonucleotides, Antisense/*pharmacology | 2 | 9.0 |
Fixatives | 3 | 4.0 |
Formaldehyde | 4 | 4.0 |
Neoplasms/*genetics/pathology | 4 | 11.0 |
Neoplasms, Experimental/genetics/pathology | 2 | 33.0 |
Paraffin Embedding | 5 | 1.0 |
RNA, Messenger/analysis/genetics/metabolism | 2 | 5.0 |
Receptor, erbB-2/genetics | 3 | 15.0 |
Tissue Fixation | 3 | 3.0 |
Cervix Neoplasms | 2 | 8.0 |
Oncogene Proteins, Viral/genetics/*metabolism | 3 | 10.0 |
Neoplasm Invasiveness/pathology | 2 | 3.0 |
Nuclear Magnetic Resonance, Biomolecular | 4 | 2.0 |
Esophageal Neoplasms/genetics/metabolism/*pathology | 2 | 40.0 |
*Plants, Medicinal | 2 | 2.0 |
Chromosome Aberrations/*genetics | 2 | 1.0 |
In Situ Hybridization, Fluorescence/*methods | 2 | 2.0 |
Adenovirus E1B Proteins/genetics/*metabolism | 2 | 33.0 |
Adenovirus E4 Proteins/genetics/*metabolism | 2 | 40.0 |
Oncogene Proteins, Viral/metabolism | 2 | 10.0 |
Cell Nucleus/drug effects/metabolism | 2 | 3.0 |
DNA/genetics | 3 | 0.0 |
Genes, ras/*genetics | 3 | 3.0 |
Protein p53/*genetics/physiology | 2 | 15.0 |
Response Elements/genetics | 2 | 1.0 |
Sequence Homology, Nucleic Acid | 6 | 0.0 |
Signal Transduction/*genetics | 2 | 1.0 |
Etoposide/*pharmacology | 4 | 12.0 |
Gene Silencing | 8 | 2.0 |
Carcinoma, Squamous Cell/*genetics | 4 | 2.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Mouth Neoplasms/*genetics | 2 | 4.0 |
Proto-Oncogenes | 10 | 5.0 |
Genes, Retinoblastoma/genetics | 4 | 12.0 |
Genes, myc/genetics | 4 | 5.0 |
Transcription Factors/genetics | 3 | 0.0 |
Genes, fos | 2 | 1.0 |
Genes, myc | 8 | 2.0 |
Neoplasm Proteins/analysis/*genetics | 4 | 12.0 |
Proto-Oncogene Proteins/analysis/genetics | 7 | 25.0 |
Retinoblastoma Protein/analysis | 8 | 23.0 |
Tumor Markers, Biological/analysis/*genetics | 4 | 19.0 |
Drug Resistance, Neoplasm/genetics | 2 | 2.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Glioblastoma/*genetics/pathology | 2 | 8.0 |
Melanoma/*metabolism | 2 | 3.0 |
*Helicobacter pylori | 2 | 1.0 |
Ubiquitin-Protein Ligases/metabolism | 4 | 9.0 |
Cell Proliferation | 3 | 1.0 |
Protein p53/*metabolism/*physiology | 2 | 50.0 |
Nuclear Proteins/genetics | 4 | 1.0 |
Proto-Oncogene Proteins/chemistry/*genetics | 2 | 8.0 |
Carcinoma, Non-Small-Cell Lung | 4 | 21.0 |
Genes, bcl-2/genetics | 2 | 5.0 |
*Antiretroviral Therapy, Highly Active | 2 | 0.0 |
Developing Countries | 2 | 2.0 |
Tuberculosis/epidemiology/*prevention & control | 2 | 20.0 |
Apoptosis/physiology/*radiation effects | 2 | 20.0 |
Transcription, Genetic/*radiation effects | 3 | 27.0 |
Tumor Cells, Cultured/radiation effects | 8 | 20.0 |
Cell Extracts | 2 | 1.0 |
Recombinant Fusion Proteins/isolation & purification/metabolism | 2 | 2.0 |
Cattle | 3 | 0.0 |
DNA/biosynthesis | 3 | 0.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Oncogene Proteins, Viral/*genetics | 2 | 3.0 |
Papillomavirus, Human/*genetics | 2 | 2.0 |
Repressor Proteins/genetics/metabolism | 2 | 2.0 |
Retinoblastoma Protein/*genetics | 2 | 4.0 |
Oncogene Proteins, Viral/*physiology | 2 | 5.0 |
Papillomavirus, Human | 3 | 8.0 |
Nuclear Proteins/genetics/*physiology | 2 | 4.0 |
Protein p53/chemistry | 2 | 50.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Down-Regulation/radiation effects | 2 | 28.0 |
Membrane Proteins/biosynthesis/genetics | 2 | 5.0 |
Frameshift Mutation | 2 | 0.0 |
Brain Neoplasms | 2 | 14.0 |
Cysteine | 2 | 1.0 |
Protein p53/*genetics/*metabolism | 3 | 21.0 |
Tyrosine | 2 | 1.0 |
Catalytic Domain | 2 | 0.0 |
Yeasts | 2 | 2.0 |
Cell Cycle/genetics | 14 | 9.0 |
Oncogene Protein p21(ras)/genetics | 2 | 50.0 |
Radiation Tolerance/*genetics | 3 | 5.0 |
Cell Fusion | 3 | 1.0 |
Codon | 7 | 1.0 |
Stem Cells/metabolism | 3 | 3.0 |
Tryptophan/chemistry | 2 | 5.0 |
Genes, p53/*radiation effects | 3 | 33.0 |
Biopsy | 7 | 0.0 |
Mouth Mucosa/pathology | 2 | 8.0 |
Aneuploidy | 2 | 1.0 |
Carcinoma, Non-Small-Cell Lung/genetics/*metabolism/pathology | 2 | 22.0 |
Nuclear Proteins/biosynthesis | 5 | 10.0 |
Tumor Markers, Biological | 5 | 1.0 |
Phosphoric Monoester Hydrolases/genetics | 4 | 5.0 |
Receptor, Epidermal Growth Factor/genetics | 10 | 9.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Bone Neoplasms/*genetics | 5 | 11.0 |
Membrane Proteins/*genetics | 3 | 0.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Cell Transformation, Viral | 3 | 1.0 |
Cyclin-Dependent Kinases/metabolism | 6 | 1.0 |
Cyclins/*genetics | 5 | 3.0 |
Microtubule-Associated Proteins/metabolism | 3 | 2.0 |
Papovaviridae Infections/genetics | 2 | 66.0 |
Retinoblastoma Protein/genetics/metabolism | 3 | 8.0 |
Mitogen-Activated Protein Kinases/physiology | 3 | 2.0 |
DNA, Neoplasm/genetics/metabolism | 3 | 3.0 |
Protein Isoforms/genetics | 2 | 0.0 |
Tobacco/*adverse effects | 2 | 25.0 |
Carcinoma/*genetics | 3 | 2.0 |
Neoplasm Invasiveness/genetics | 2 | 4.0 |
*Cell Cycle | 5 | 2.0 |
Cyclins/physiology | 2 | 5.0 |
Mitosis | 3 | 0.0 |
Neoplasms/*metabolism/*pathology | 2 | 15.0 |
Peptide Fragments/chemistry/metabolism | 3 | 2.0 |
Proto-Oncogene Proteins/*chemistry/genetics/*metabolism | 4 | 21.0 |
*Transfection | 2 | 0.0 |
Antimetabolites, Antineoplastic/pharmacology | 4 | 4.0 |
Bladder/metabolism | 2 | 10.0 |
*Gene Expression Regulation, Neoplastic/drug effects | 4 | 7.0 |
DNA, Complementary/metabolism | 6 | 0.0 |
Mice, Inbred C57BL | 9 | 0.0 |
T-Lymphocytes/cytology | 2 | 2.0 |
Tissue Distribution | 5 | 0.0 |
Metalloendopeptidases/biosynthesis | 3 | 15.0 |
Cell Cycle/*genetics | 6 | 8.0 |
Genes, Retinoblastoma/physiology | 2 | 33.0 |
Genes, p53/physiology | 2 | 7.0 |
Antibodies, Monoclonal | 6 | 0.0 |
Antigens, Neoplasm/analysis | 3 | 0.0 |
Tumor Suppressor Proteins/metabolism | 3 | 2.0 |
DNA-Binding Proteins/metabolism/*physiology | 3 | 2.0 |
*Neoplasm Proteins | 2 | 0.0 |
Nuclear Proteins/metabolism/*physiology | 2 | 6.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 0.0 |
Transcription Factors/metabolism/*physiology | 3 | 3.0 |
*Genetic Markers | 2 | 0.0 |
Confidence Intervals | 2 | 0.0 |
RNA, Messenger/*metabolism | 6 | 0.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
ras Proteins/physiology | 2 | 6.0 |
Proteins/*physiology | 3 | 1.0 |
Protein p53/analysis/genetics/*metabolism | 2 | 66.0 |
Proto-Oncogene Protein p21(ras)/genetics/*metabolism | 2 | 33.0 |
Mouth Neoplasms/*genetics/metabolism/pathology | 2 | 66.0 |
Neoplasms, Experimental/*therapy | 3 | 13.0 |
Proto-Oncogene Proteins/*chemistry/*metabolism | 2 | 11.0 |
Ovarian Neoplasms/*pathology | 2 | 3.0 |
Antineoplastic Agents/*therapeutic use | 3 | 0.0 |
Drug Design | 4 | 1.0 |
Lysine/metabolism | 2 | 2.0 |
Ubiquitin/genetics/*metabolism | 2 | 33.0 |
Chromosomes, Human, Pair 12 | 15 | 9.0 |
Liposarcoma, Myxoid/*genetics/pathology | 2 | 100.0 |
*Drug Design | 3 | 3.0 |
Protein p53/*chemistry/metabolism | 2 | 50.0 |
Surface Plasmon Resonance | 3 | 1.0 |
Down-Regulation/*physiology | 2 | 6.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Receptors, Estrogen/analysis | 2 | 0.0 |
Receptors, Progesterone/analysis | 2 | 0.0 |
Nuclear Proteins/*analysis | 5 | 2.0 |
Antigens, Polyomavirus Transforming/analysis/genetics | 3 | 100.0 |
Cyclins/*physiology | 3 | 5.0 |
DNA Fragmentation | 4 | 1.0 |
Embryo | 3 | 0.0 |
Genes, Lethal | 2 | 2.0 |
Proto-Oncogene Proteins/deficiency/genetics/*physiology | 3 | 27.0 |
Recombinant Fusion Proteins/biosynthesis/physiology | 2 | 18.0 |
Dogs | 4 | 0.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Transcription Factors/*chemistry/genetics/*metabolism | 2 | 6.0 |
Casein Kinases | 3 | 6.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Lipoma/genetics/metabolism | 2 | 100.0 |
Genes, Tumor Suppressor/genetics | 4 | 2.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Bile Duct Neoplasms/*genetics/metabolism/pathology | 2 | 66.0 |
Protein Binding/genetics | 2 | 0.0 |
Recombinant Proteins | 2 | 0.0 |
Promoter Regions (Genetics)/physiology | 3 | 1.0 |
G2 Phase | 3 | 1.0 |
Gene Targeting | 2 | 0.0 |
*Protein Kinases | 2 | 3.0 |
Stem Cells/cytology/metabolism | 2 | 4.0 |
Chromosome Mapping | 23 | 0.0 |
Genes, erbB-2 | 2 | 2.0 |
Carrier Proteins/physiology | 2 | 1.0 |
Nuclear Localization Signal/physiology | 2 | 18.0 |
Open Reading Frames | 3 | 0.0 |
Cohort Studies | 3 | 0.0 |
Neoplasm Recurrence, Local/pathology | 3 | 5.0 |
Bladder Neoplasms/*genetics | 5 | 6.0 |
Proto-Oncogenes/genetics | 2 | 6.0 |
Biological Markers/analysis | 3 | 0.0 |
Granuloma, Giant Cell/*pathology | 2 | 40.0 |
Proliferating Cell Nuclear Antigen/*analysis | 3 | 1.0 |
Breast Neoplasms/metabolism/*pathology | 3 | 3.0 |
X-Rays | 2 | 1.0 |
Astrocytoma/*genetics/*pathology | 2 | 40.0 |
Astrocytoma/*genetics/pathology | 2 | 8.0 |
Protein p53/genetics/metabolism | 12 | 12.0 |
Drug Stability | 6 | 2.0 |
DNA, Neoplasm/*genetics | 3 | 1.0 |
Biological Transport | 2 | 0.0 |
Neoplasm Proteins/metabolism/*physiology | 2 | 18.0 |
Cyclin-Dependent Kinases/genetics/*metabolism | 2 | 3.0 |
Histiocytoma, Fibrous/genetics/metabolism/*pathology | 2 | 66.0 |
Liposarcoma/genetics/metabolism/*pathology | 2 | 66.0 |
Retroperitoneal Neoplasms/genetics/metabolism/*pathology | 2 | 100.0 |
Dog Diseases/*genetics | 2 | 9.0 |
Genes, Retinoblastoma/*genetics | 4 | 9.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Brain Neoplasms/*genetics/mortality | 2 | 40.0 |
Phosphoric Monoester Hydrolases/*genetics | 2 | 0.0 |
Neoplasm Recurrence, Local/*metabolism/pathology | 2 | 25.0 |
Adenocarcinoma/*metabolism | 2 | 2.0 |
Adenoma/metabolism | 2 | 5.0 |
Colon/metabolism | 2 | 1.0 |
Protein p53/deficiency/genetics/*metabolism | 2 | 18.0 |
Neoplasm Proteins/*analysis/genetics | 2 | 4.0 |
Bacterial Proteins/metabolism | 2 | 3.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
Oncogene Proteins, Viral/*metabolism | 4 | 11.0 |
Oxygen/*metabolism | 2 | 1.0 |
Repressor Proteins/metabolism | 3 | 1.0 |
Microtubules/metabolism | 2 | 1.0 |
Neoplasm Proteins/genetics/*physiology | 3 | 6.0 |
Alkaline Phosphatase/metabolism | 2 | 1.0 |
DNA Damage/*physiology | 2 | 4.0 |
Threonine/chemistry | 2 | 2.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
*Chromosomes, Human, Pair 17 | 3 | 0.0 |
Testis/metabolism | 3 | 1.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/*physiology | 9 | 5.0 |
Herpesvirus 4, Human/genetics/*isolation & purification | 2 | 11.0 |
Hodgkin Disease/*genetics/virology | 2 | 100.0 |
RNA, Viral/genetics | 2 | 2.0 |
Retinoblastoma Protein/genetics | 3 | 8.0 |
Lymphoma, Follicular/metabolism | 2 | 100.0 |
Lymphoma, Mantle-Cell/metabolism | 2 | 100.0 |
Lymphoma, Mucosa-Associated Lymphoid Tissue/metabolism | 2 | 40.0 |
Lymphoma, Non-Hodgkin/*metabolism | 2 | 22.0 |
Antigens, CD44/analysis | 2 | 2.0 |
Cell Cycle Proteins/physiology | 3 | 7.0 |
Leiomyosarcoma/*chemistry/genetics | 2 | 100.0 |
Monosaccharide Transport Proteins/analysis | 2 | 33.0 |
Uterine Neoplasms/*chemistry/genetics | 2 | 100.0 |
Osteosarcoma/*genetics/physiopathology | 3 | 100.0 |
Point Mutation/genetics/*physiology | 2 | 33.0 |
Radiobiology | 2 | 15.0 |
*DNA Damage/radiation effects | 2 | 20.0 |
Peptides/chemistry | 4 | 1.0 |
Sensitivity and Specificity | 5 | 0.0 |
Neoplasm Proteins/analysis/genetics | 3 | 12.0 |
Carcinoma, Non-Small-Cell Lung/*genetics/pathology | 3 | 10.0 |
Proto-Oncogene Proteins/*pharmacology | 2 | 14.0 |
Transforming Growth Factor beta/physiology | 2 | 2.0 |
Rhabdomyosarcoma/*genetics | 4 | 19.0 |
Enzyme Stability | 2 | 1.0 |
Cell Transformation, Neoplastic/*genetics | 5 | 2.0 |
Chromosomes, Human, Pair 17/*genetics | 2 | 1.0 |
Tumor Stem Cell Assay | 3 | 1.0 |
Cell Survival/genetics | 2 | 3.0 |
Proto-Oncogene Proteins/*biosynthesis/metabolism | 2 | 40.0 |
Genes, p16/*genetics | 2 | 4.0 |
Skin Neoplasms/*genetics | 2 | 1.0 |
Papillomavirus, Human/*metabolism | 2 | 18.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
Mouth Neoplasms/*metabolism | 2 | 8.0 |
Precancerous Conditions/metabolism | 2 | 12.0 |
Smoking/adverse effects | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Spodoptera | 2 | 0.0 |
Proto-Oncogene Proteins/analysis/*biosynthesis | 5 | 20.0 |
*Gene Dosage | 2 | 2.0 |
Bromodeoxyuridine/pharmacology | 2 | 3.0 |
Reading Frames | 2 | 11.0 |
Signal Transduction/drug effects | 2 | 0.0 |
Sequence Analysis | 4 | 1.0 |
Expressed Sequence Tags | 3 | 0.0 |
Organ Specificity | 3 | 0.0 |
Receptor, Epidermal Growth Factor/analysis | 3 | 1.0 |
Soft Tissue Neoplasms/*genetics | 5 | 19.0 |
Carrier Proteins/*genetics/metabolism | 2 | 0.0 |
Cell Cycle Proteins/*genetics/metabolism | 2 | 3.0 |
NIH 3T3 Cells | 6 | 2.0 |
Antigens, CD95/*metabolism | 2 | 1.0 |
Up-Regulation/drug effects | 4 | 1.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 3 | 1.0 |
Gene Expression/drug effects | 3 | 0.0 |
Exons/*genetics | 3 | 0.0 |
Protein Binding/physiology | 6 | 2.0 |
Neoplasm Proteins/*physiology | 4 | 4.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
Fibrosarcoma/*genetics | 2 | 40.0 |
Gene Expression Regulation, Neoplastic/*genetics | 7 | 3.0 |
Nuclear Proteins/*antagonists & inhibitors | 2 | 25.0 |
Protein Synthesis Inhibitors/*pharmacology | 2 | 6.0 |
Protein p53/*isolation & purification | 2 | 100.0 |
Proto-Oncogene Proteins/*isolation & purification | 2 | 40.0 |
Breast Neoplasms/*chemistry/genetics | 2 | 15.0 |
Carcinoma, Ductal, Breast/*genetics | 2 | 8.0 |
Gene Expression Regulation/genetics | 6 | 3.0 |
Trans-Activation (Genetics)/genetics | 2 | 2.0 |
Adenovirus E1A Proteins/*metabolism | 3 | 10.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Antibodies/pharmacology | 2 | 0.0 |
DNA Damage/*genetics | 2 | 3.0 |
Dichlororibofuranosylbenzimidazole/pharmacology | 2 | 7.0 |
Transcription, Genetic/radiation effects | 4 | 21.0 |
Molecular Biology | 2 | 0.0 |
Breast Neoplasms/genetics/*metabolism | 3 | 5.0 |
Cell Differentiation/physiology | 5 | 1.0 |
Neoplasm Proteins/*genetics/*metabolism | 3 | 17.0 |
Protein p53/genetics/metabolism/*physiology | 3 | 50.0 |
Proto-Oncogene Proteins/analysis/*physiology | 2 | 28.0 |
Membrane Proteins/genetics/*metabolism | 2 | 0.0 |
Bromodeoxyuridine/metabolism | 2 | 2.0 |
Protein p53/analysis/*biosynthesis | 6 | 27.0 |
Protein p16/analysis | 2 | 10.0 |
Protein p16/genetics/*metabolism | 3 | 16.0 |
Biological Markers | 2 | 0.0 |
Growth Substances/metabolism | 2 | 1.0 |
Cervix Uteri/metabolism | 2 | 11.0 |
Staining and Labeling | 2 | 0.0 |
Osteosarcoma/*metabolism | 2 | 14.0 |
*Proto-Oncogene Proteins | 25 | 1.0 |
*Proto-Oncogenes | 7 | 1.0 |
Solubility | 2 | 0.0 |
Cell Cycle/*genetics/*physiology | 2 | 50.0 |
Chromosomes, Human, Pair 12/genetics | 3 | 3.0 |
DNA Probes | 7 | 0.0 |
*Ring Chromosomes | 2 | 6.0 |
*Genes, Retinoblastoma | 5 | 4.0 |
Papillomavirus, Human/*isolation & purification | 2 | 7.0 |
DNA Damage/radiation effects | 2 | 9.0 |
Ligases/*antagonists & inhibitors | 2 | 40.0 |
Breast Neoplasms/*genetics/metabolism | 2 | 1.0 |
RNA/metabolism | 2 | 0.0 |
Osteosarcoma/*genetics | 2 | 6.0 |
Liposarcoma/genetics | 3 | 60.0 |
*Gene Rearrangement | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/analysis/genetics | 2 | 12.0 |
Crosses, Genetic | 3 | 0.0 |
Neoplasms, Experimental/*genetics/pathology | 2 | 25.0 |
Introns | 3 | 0.0 |
Lung Neoplasms/*genetics/*metabolism | 2 | 40.0 |
Neoplasm Proteins/immunology/*metabolism | 2 | 13.0 |
Protease Inhibitors/pharmacology | 2 | 0.0 |
Adenocarcinoma/*genetics/metabolism | 3 | 7.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Antibodies | 2 | 0.0 |
Transcription, Genetic/genetics | 5 | 1.0 |
Receptor, Epidermal Growth Factor/*genetics | 2 | 0.0 |
Microscopy, Phase-Contrast | 2 | 2.0 |
Carcinoma, Squamous Cell/chemistry/pathology | 2 | 18.0 |
Up-Regulation/physiology | 2 | 1.0 |
Neoplasms/*genetics | 8 | 3.0 |
Melanoma/genetics | 2 | 5.0 |
Neoplasms/*genetics/metabolism | 3 | 10.0 |
Proteins/metabolism/*physiology | 2 | 4.0 |
DNA, Neoplasm/analysis/genetics | 3 | 3.0 |
Cloning, Molecular/methods | 2 | 1.0 |
Glutathione Transferase/genetics/metabolism | 2 | 1.0 |
Trans-Activators/chemistry/genetics/*metabolism | 2 | 2.0 |
Flavonoids/*pharmacology | 2 | 2.0 |
Piperidines/*pharmacology | 2 | 3.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 4 | 0.0 |
U937 Cells | 2 | 0.0 |
*Apoptosis/genetics | 2 | 5.0 |
Liposarcoma/*genetics | 4 | 66.0 |
*Heterozygote | 2 | 0.0 |
Lipoma/genetics/pathology | 2 | 66.0 |
Sarcoma/*genetics/*pathology | 3 | 75.0 |
Soft Tissue Neoplasms/*genetics/pathology | 2 | 20.0 |
Adenovirus E1A Proteins/*physiology | 2 | 10.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Cyclins/drug effects/genetics | 2 | 50.0 |
*Databases, Factual | 2 | 3.0 |
Soft Tissue Neoplasms/genetics | 3 | 50.0 |
Oxidation-Reduction | 2 | 0.0 |
Trans-Activation (Genetics)/drug effects | 2 | 0.0 |
Neoplasms/*metabolism | 4 | 4.0 |
*Cell Transformation, Viral | 2 | 1.0 |
Transcription Factor TFIID | 2 | 1.0 |
Transcription Factors, TFII/metabolism | 2 | 5.0 |
Brain Neoplasms/genetics/*metabolism/pathology | 2 | 16.0 |
Ultraviolet Rays/adverse effects | 2 | 3.0 |
Proto-Oncogene Proteins c-bcl-2/physiology | 2 | 4.0 |
RNA-Directed DNA Polymerase | 2 | 1.0 |
Lymphoma, B-Cell/*genetics | 2 | 2.0 |
Adenocarcinoma/metabolism/pathology | 2 | 3.0 |
Neoplasm Proteins/physiology | 2 | 3.0 |
Lung Neoplasms/*genetics/metabolism | 2 | 5.0 |
p14ARF Protein/*analysis/genetics | 2 | 100.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Neoplasms/*therapy | 2 | 1.0 |
Proto-Oncogene Proteins/*biosynthesis/genetics/physiology | 2 | 25.0 |
Gene Expression/radiation effects | 3 | 15.0 |
Neoplasm Proteins/analysis/biosynthesis | 5 | 55.0 |
Risk | 2 | 0.0 |
G1 Phase/drug effects | 2 | 1.0 |
MAP Kinase Signaling System | 2 | 0.0 |
Astrocytoma/*genetics | 3 | 6.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Leupeptins/pharmacology | 4 | 3.0 |
*Genome, Human | 2 | 0.0 |
Antineoplastic Agents/chemical synthesis | 2 | 66.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
*Transcription, Genetic/drug effects | 2 | 1.0 |
G1 Phase/*genetics | 3 | 14.0 |
*Trans-Activation (Genetics)/drug effects | 2 | 4.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Liver/drug effects/*metabolism | 2 | 2.0 |
Pedigree | 2 | 0.0 |
Neoplasm Proteins/biosynthesis/*genetics | 2 | 2.0 |
Membrane Glycoproteins/*pharmacology | 2 | 2.0 |
Ubiquitin-Protein Ligases/genetics/metabolism | 2 | 22.0 |
Postoperative Period | 2 | 0.0 |
Oligonucleotides, Antisense | 2 | 2.0 |
Cell-Free System | 2 | 0.0 |
Genes, ras/genetics | 2 | 1.0 |
Lymphocyte Activation/genetics | 2 | 2.0 |
Chromosomes, Human, Pair 1/genetics | 2 | 1.0 |
Gene Rearrangement | 5 | 1.0 |
Protein p53/drug effects/*metabolism | 2 | 33.0 |
Enzyme Inhibitors | 2 | 2.0 |
Leiomyosarcoma/*genetics | 2 | 66.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
Ribosomal Proteins/metabolism | 2 | 15.0 |
Proto-Oncogenes/*genetics | 6 | 8.0 |
Embryonic and Fetal Development/*physiology | 2 | 4.0 |
Enzyme Inhibitors/*metabolism | 4 | 5.0 |
Brain Neoplasms/*genetics/metabolism | 2 | 7.0 |
Protein p53/antagonists & inhibitors/*metabolism | 3 | 60.0 |
DNA Repair/genetics | 3 | 1.0 |
Herpesvirus 4, Human/isolation & purification | 2 | 3.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Polymerase Chain Reaction/*methods | 3 | 0.0 |
Oncogenes/genetics | 2 | 2.0 |
Fibroblasts/drug effects/metabolism | 2 | 1.0 |
Histiocytoma, Fibrous/*genetics | 2 | 50.0 |
Protein p53/biosynthesis/genetics/*metabolism | 2 | 40.0 |
Proto-Oncogene Proteins/biosynthesis/genetics/*metabolism | 2 | 15.0 |
Astrocytoma/genetics | 2 | 8.0 |
Glioma/*genetics | 4 | 5.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Reed-Sternberg Cells/metabolism | 2 | 33.0 |
Nuclear Proteins/antagonists & inhibitors/metabolism | 2 | 66.0 |
Proto-Oncogene Proteins c-bcl-2 | 2 | 1.0 |
Fetus | 2 | 0.0 |
CDC2 Protein Kinase/metabolism | 2 | 1.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Lymphatic Metastasis/genetics | 2 | 7.0 |
Carcinoma in Situ/genetics | 2 | 10.0 |
Carcinoma, Ductal, Breast/genetics | 2 | 11.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
DNA, Viral/analysis | 2 | 0.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Kidney/metabolism | 2 | 0.0 |
Lentivirus/genetics | 2 | 6.0 |
Nuclear Proteins/*biosynthesis | 2 | 4.0 |
Protein Isoforms/metabolism | 2 | 1.0 |
Genes, erbB-1 | 2 | 11.0 |
Proto-Oncogene Proteins/*immunology | 2 | 25.0 |
Apoptosis/*drug effects/radiation effects | 3 | 23.0 |
Lipoma/*genetics | 2 | 18.0 |
Acetyltransferases/metabolism | 4 | 5.0 |
Histones/*metabolism | 2 | 1.0 |
*CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
Oncogene Proteins/*genetics | 2 | 1.0 |
Proto-Oncogene Proteins/*chemistry | 2 | 9.0 |
Peptides/genetics/metabolism | 2 | 4.0 |
*Protein Conformation | 2 | 0.0 |
Cell Cycle/drug effects/genetics | 2 | 11.0 |
Radiation Tolerance/*drug effects | 2 | 11.0 |
DNA-Binding Proteins/biosynthesis | 2 | 2.0 |
RNA, Neoplasm/*analysis | 2 | 4.0 |
Leukemia/*genetics | 2 | 1.0 |
Carcinoma, Transitional Cell/*genetics | 3 | 9.0 |
Retroperitoneal Neoplasms/*genetics/pathology | 2 | 66.0 |
Nuclear Proteins/*metabolism/*physiology | 2 | 28.0 |
Restriction Mapping | 2 | 0.0 |
Soft Tissue Neoplasms/classification/*genetics/pathology | 2 | 100.0 |
Gene Expression/genetics | 4 | 1.0 |
Cell Aging | 2 | 2.0 |
NF-kappa B/genetics/*metabolism | 2 | 2.0 |
Genes, p53/*genetics/physiology | 2 | 33.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Neoplasms/genetics/metabolism/pathology | 2 | 22.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Ubiquitin-Protein Ligases/chemistry | 2 | 66.0 |
Crystallography, X-Ray | 3 | 0.0 |
Hydrophobicity | 2 | 2.0 |
Gene Expression Profiling/methods | 3 | 4.0 |
Lipoma/diagnosis/*genetics | 2 | 100.0 |
Saccharomyces cerevisiae Proteins/genetics | 2 | 5.0 |
Fluorouracil/pharmacology | 2 | 3.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 3 | 0.0 |
Boronic Acids/*pharmacology | 2 | 22.0 |
Pyrazines/*pharmacology | 2 | 6.0 |
Oligonucleotide Array Sequence Analysis/methods | 2 | 2.0 |
Stomach Neoplasms/*genetics | 2 | 1.0 |
*RNA Processing, Post-Transcriptional | 2 | 3.0 |
Staurosporine/*pharmacology | 2 | 10.0 |
Annexin A5/metabolism | 2 | 2.0 |
Cell Cycle Proteins/*biosynthesis/genetics | 2 | 12.0 |
Retinoblastoma Protein/biosynthesis/genetics | 2 | 18.0 |
Apoptosis/genetics/radiation effects | 3 | 30.0 |
Protein p53/*metabolism/physiology | 2 | 40.0 |
Cytoskeletal Proteins/metabolism | 3 | 1.0 |
Carcinoma, Squamous Cell/genetics/*metabolism/pathology | 2 | 8.0 |
Genes, p53/genetics/physiology | 2 | 50.0 |
Ubiquitin | 2 | 40.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Carcinoma, Squamous Cell/*genetics/pathology/*radiotherapy | 2 | 100.0 |
Trisomy | 2 | 1.0 |
Lung Neoplasms/genetics/metabolism/pathology | 2 | 20.0 |
Membrane Glycoproteins/pharmacology | 2 | 3.0 |
Signal Transduction/drug effects/physiology | 2 | 0.0 |
Base Pair Mismatch | 2 | 1.0 |
Reference Values | 2 | 0.0 |
Retinoblastoma Protein/*physiology | 2 | 6.0 |
Proto-Oncogene Proteins/deficiency/genetics/*metabolism | 2 | 22.0 |
Pyrimidines/*pharmacology | 2 | 3.0 |
Gene Expression/*drug effects | 2 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |